Skip to content Skip to footer
Subscribe Now
NEWS

Philochem and RayzeBio Enter Into a Development and Commercialization Deal of ~$1.35B

Shots: Philochem and RayzeBio (BMS) entered into a development and commercialization agreement under which Philochem granted RayzeBio exclusive worldwide rights to develop, manufacture, and commercialize its radiopharmaceutical agent OncoACP3 for prostate cancer  Under the agreement, Philochem will receive $350M up front and is eligible for up to $1B in development, regulatory, and commercial milestones, plus…
June 11, 2025

Read more

NEWS

OS Therapies & EVERSANA Partner to Commercialize OST-HER2 in the US for Pediatric Osteosarcoma

Shots: OS Therapies joined hands with EVERSANA to commercialize OST-HER2 in the US for the treatment of pediatric lung metastatic osteosarcoma This partnership leverages EVERSANA’s integrated commercialization platform, including market access, medical affairs, field deployment, patient services, and stakeholder engagement enabling OS Therapies to bring OST-HER2 to market rapidly and cost-effectively OS Therapies recently secured…
June 11, 2025

Read more

Daiichi Sankyo
NEWS

Daiichi Sankyo Reports First Patient Dosing in P-III (DESTINY-Endometrial01) Study Evaluating ENHERTU

Shots : Daiichi reported the first patient dosing in a P-III (DESTINY-Endometrial01) study evaluating ENHERTU (trastuzumab deruxtecan) + rilvegostomig or pembrolizumab vs Pt. chemotx. (carboplatin and paclitaxel) + pembrolizumab as 1L therapy, in HER2-expressing (IHC 3+/2+), pMMR advanced or recurrent endometrial cancer pts The study is assessing the efficacy and safety of ENHERTU (5.4 mg/kg)…
June 10, 2025

Read more

TOP 20

Top 20 Diagnostics Companies of 2025 

Top 20 Diagnostics Companies of 2025  Shots:  Driven by continuous innovation and enhanced precision, the diagnostic industry is advancing rapidly, transforming the way healthcare is delivered  In 2025, the global diagnostic testing market is valued at approximately $207.96B in 2025 and is projected to grow to around $272.9B by 2034, reflecting a CAGR of 3%.…
May 29, 2025

Read more

Top 20 Medical device companies of 2025
TOP 20

Top 20 Medical Device Companies of 2025

Shots:  Driven by continuous innovation, the MedTech sector is evolving rapidly to enhance preventive, diagnostic, and therapeutic capabilities in healthcare In 2023, the global MedTech market was valued at $668.2B and is projected to reach $989.1B by 2033, growing at a CAGR of approximately 4%. Medtronic led the industry with a revenue of $33.12B, followed…
May 22, 2025

Read more

Ramsoft & Therapixel
NEWS

RamSoft and Therapixel Form a Commercial Partnership For an Integrated AI Breast Imaging Solution

Shots: RamSoft Inc. and Therapixel have entered into a commercial partnership to integrate Therapixel’s MammoScreen AI-powered breast imaging software into RamSoft’s PowerServer and OmegaAI platforms This collaboration integrates Therapixel's MammoScreen, breast imaging AI, directly into RamSoft's platforms Recent studies showed that MammoScreen improves radiologist performance with 8% higher sensitivity, 2% higher specificity, and 24% faster…
May 21, 2025

Read more

Kalivir Immunotherapeutics
NEWS

KaliVir Immunotherapeutics Reports Completion of First Cohort of P-I/Ib (STEALTH-001) Study in Advanced Solid Tumors

Shots: KaliVir Immunotherapeuticsreported completion of the first cohort in P-I/Ib (STEALTH-001) study evaluating VET3-TGI as a monotx. and in combination with a checkpoint inhibitor in advanced, unresectable, or metastatic solid tumor pts.  The Data Safety Committee reviewed initial safety data and approved the progression of VET3-TGI to the next IT and IV dosing cohorts VET3-TGI is an…
May 21, 2025

Read more

Load more